Swiss National Bank Has $300.86 Million Stake in Bristol Myers Squibb Company $BMY

Key Points

• Swiss National Bank reduced its Bristol Myers Squibb stake by 4.9% in the fourth quarter, selling 288,600 shares and leaving it with 5.58 million shares valued at about $300.86 million.
• Wall Street sentiment is mixed on BMY, with analysts split between buy and hold ratings; the stock currently carries an overall Hold consensus and an average price target of $61.31.
• Bristol Myers Squibb topped quarterly expectations, reporting EPS of $1.58 on revenue of $11.49 billion, while also noting FY 2026 EPS guidance of 6.05 to 6.35.

Swiss National Bank decreased its stake in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 4.9% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 5,577,700 shares of the biopharmaceutical company's stock after selling 288,600 shares during the quarter. Swiss National Bank owned about 0.27% of Bristol Myers Squibb worth $300,861,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently modified their holdings of BMY. Brighton Jones LLC grew its position in shares of Bristol Myers Squibb by 33.4% during the 4th quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company's stock worth $1,116,000 after buying an additional 4,935 shares during the period. Sivia Capital Partners LLC grew its position in shares of Bristol Myers Squibb by 59.4% during the 2nd quarter. Sivia Capital Partners LLC now owns 7,477 shares of the biopharmaceutical company's stock worth $346,000 after buying an additional 2,786 shares during the period. United Bank grew its position in shares of Bristol Myers Squibb by 15.0% during the 2nd quarter. United Bank now owns 25,148 shares of the biopharmaceutical company's stock worth $1,164,000 after buying an additional 3,277 shares during the period. Marshall Wace LLP acquired a new stake in Bristol Myers Squibb in the 2nd quarter valued at $221,000. Finally, Nebula Research & Development LLC acquired a new stake in Bristol Myers Squibb in the 2nd quarter valued at $405,000. Institutional investors and hedge funds own 76.41% of the company's stock.

Wall Street Analyst Weigh In

Several analysts recently issued reports on BMY shares. Citigroup reissued a "neutral" rating on shares of Bristol Myers Squibb in a research report on Friday, May 1st. Guggenheim reissued a "buy" rating and issued a $72.00 price target on shares of Bristol Myers Squibb in a research report on Wednesday, April 8th. Cantor Fitzgerald lifted their price target on shares of Bristol Myers Squibb from $45.00 to $54.00 and gave the company a "neutral" rating in a research report on Wednesday, April 8th. Royal Bank Of Canada started coverage on shares of Bristol Myers Squibb in a research report on Tuesday, February 24th. They issued a "sector perform" rating and a $60.00 price target for the company. Finally, Piper Sandler reissued an "overweight" rating and issued a $75.00 price target (up from $66.00) on shares of Bristol Myers Squibb in a research report on Monday, February 23rd. Eight investment analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and a consensus price target of $61.31.

Insider Transactions at Bristol Myers Squibb

In other Bristol Myers Squibb news, EVP David V. Elkins sold 30,000 shares of Bristol Myers Squibb stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $61.67, for a total transaction of $1,850,100.00. Following the transaction, the executive vice president directly owned 159,248 shares of the company's stock, valued at $9,820,824.16. The trade was a 15.85% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.05% of the stock is owned by corporate insiders.

Bristol Myers Squibb Price Performance

BMY opened at $56.96 on Friday. The company has a debt-to-equity ratio of 2.10, a current ratio of 1.42 and a quick ratio of 1.28. The company has a market capitalization of $116.31 billion, a price-to-earnings ratio of 16.00, a P/E/G ratio of 0.16 and a beta of 0.24. The firm's fifty day moving average price is $57.83 and its two-hundred day moving average price is $56.87. Bristol Myers Squibb Company has a 1 year low of $42.52 and a 1 year high of $62.89.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last posted its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.42 by $0.16. The firm had revenue of $11.49 billion for the quarter, compared to the consensus estimate of $10.93 billion. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The business's revenue for the quarter was up 2.6% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.80 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, analysts anticipate that Bristol Myers Squibb Company will post 6.32 earnings per share for the current fiscal year.

Key Headlines Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Erste Group’s FY2026 earnings estimate for Bristol Myers Squibb stayed in line with Wall Street expectations, reinforcing the view that current earnings are stable and the stock remains attractively valued.
• Positive Sentiment: Zacks highlighted Bristol Myers Squibb as a top-ranked value stock, which may attract income- and value-focused investors looking for defensive healthcare exposure.
• Neutral Sentiment: Analyst revisions were mixed overall, with a small downward tweak to FY2027 EPS but a slightly higher FY2026 forecast, suggesting limited near-term estimate pressure.
• Negative Sentiment: Takeda reported that its AI-designed psoriasis drug, zasocitinib, outperformed BMY’s approved psoriasis treatment Sotyktu in a head-to-head study, raising competitive concerns for one of Bristol Myers Squibb’s growth products. Article Title

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.